Parabilis Medicines Inc.
PBLS | NASDAQ
$27.75
-$0.57 (-2.01%)
Nov 2, 2026, 10:37 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 |
|---|---|---|---|---|
Net Income | -52.46M | -45.32M | -34.81M | -38.33M |
Depreciation & Amortization | 593K | 606K | 618K | 654K |
Stock-Based Compensation | 3.63M | 1.3M | 823K | 852K |
Other Working Capital | 36.97M | -4.32M | -275K | -2.64M |
Other Non-Cash Items | 7.1M | 1.74M | 2.55M | 1.8M |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | 37.52M | -7.53M | -275K | 871K |
Operating Cash Flow | -3.62M | -49.2M | -31.09M | -34.15M |
Capital Expenditures | -616K | -369K | -16K | -74K |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | -33.45M | n/a | n/a | -16.66M |
Sales Maturities Of Investments | n/a | n/a | 24.53M | 23.43M |
Other Investing Acitivies | n/a | n/a | n/a | n/a |
Investing Cash Flow | -34.06M | -369K | 24.51M | 6.69M |
Debt Repayment | -3.91M | -3.9M | -144K | -140K |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -2.54M | 50M | n/a | n/a |
Financial Cash Flow | 795.71M | 350.9M | -135K | 67.29M |
Net Cash Flow | 758.02M | 301.33M | -6.71M | 39.82M |
Free Cash Flow | -4.24M | -49.57M | -31.11M | -34.23M |
Adj. Free Cash Flow | -7.87M | -50.87M | -31.93M | -35.08M |
Maintenance CapEx | -593K | -369K | -16K | -74K |
Growth CapEx | -23K | n/a | n/a | n/a |
Owner Earnings | -4.22M | -49.57M | -31.11M | -34.23M |
Add to Watchlist
Select watchlists to add or remove PBLS